NEW YORK (GenomeWeb News) – Leerink Swann today downgraded Fluidigm to Market Perform, saying the company "could take a breather in the near term" after a 30 percent spike in its stock since the start of the year.

In lowering Fluidigm from a previous Outperform rating, analyst Dan Leonard added that he sees "better risk/reward" in Genomic Health and Luminex.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.